First in human study of the infusion of ARI0003 cells in relapsed/refractory to treatment B-cell aggressive lymphoma
Phase 1
Recruiting
- Conditions
- Relapsed/refractory B-cell aggressive lymphomaMedDRA version: 21.1Level: PTClassification code: 10065857Term: Primary effusion lymphoma Class: 100000004864MedDRA version: 21.1Level: PTClassification code: 10065039Term: Plasmablastic lymphoma Class: 100000004864MedDRA version: 21.0Level: PTClassification code: 10036710Term: Primary mediastinal large B-cell lymphoma Class: 100000004864MedDRA version: 21.0Level: LLTClassification code: 10069643Term: Intravascular large B-cell lymphoma Class: 10029104MedDRA version: 21.0Level: PTClassification code: 10006598Term: Burkitt's lymphoma recurrent Class: 100000004864MedDRA version: 21.1Level: PTClassification code: 10008958Term: Chronic lymphocytic leukaemia Class: 100000004864MedDRA version: 20.1Level: LLTClassification code: 10080211Term: T-cell/histiocyte-rich large B-cell lymphoma Class: 10029104MedDRA version: 20.1Level: PTClassification code: 10080215Term: High-grade B-cell lymphoma Class: 100000004864MedDRA version: 20.1Level: PTClassification code: 10079945Term: Cutaneous lymphoma Class: 100000004864
- Registration Number
- CTIS2023-507213-97-00
- Lead Sponsor
- Fundacio De Recerca Clinic Barcelona-Institut D’investigacions Biomediques August Pi I Sunyer
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method